Aandelen in “Farmaceutica”

Aandeel Datum Koers Evolutie
vlag Harmony Biosciences Holdings Inc 5/12 39,830 USD
+4,13% 		+4,13%
vlag Harrow Health Inc 5/12 45,750 USD
-2,18% 		-2,18%
vlag HLS Therapeutics Inc 5/12 4,860 CAD
-1,02% 		-1,02%
vlag Hookipa Pharma Inc 5/12 0,860 USD
-0,58% 		-0,58%
vlag Hoth Therapeutics Inc 5/12 1,200 USD
+0,84% 		+0,84%
vlag Hutchison China Meditech Ltd. 5/12 213,000 GBX
-0,47% 		-0,47%
vlag Hutchison China Meditech Ltd. 5/12 14,220 USD
+0,42% 		+0,42%
vlag Hyloris 5/12 6,000 EUR
-1,32% 		-1,32%

Nieuws over “Farmaceutica”

7/12 · Lilly's Jaypirca (pirtobrutinib) met its primary endpoint in first-of-its-kind, head-to-head Phase 3 study versus Imbruvica (ibrutinib) · Persbericht

7/12 · Lilly's Jaypirca (pirtobrutinib) met its primary endpoint in first-of-its-kind, head-to-head Phase 3 study versus Imbruvica (ibrutinib) · Persbericht

6/12 · Earlier use of CARVYKTI® demonstrated lasting treatment-free remissions at 2.5 years in patients with relapsed or refractory multiple myeloma · Persbericht

6/12 · Viatris Announces Agreement to Monetize its Equity Stake in Biocon Biologics Limited · Persbericht

6/12 · Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) · Persbericht

5/12 · Johnson & Johnson's INLEXZO™ (gemcitabine intravesical system) delivers 74 percent disease-free survival at one year in BCG-unresponsive, high-risk, papillary-only NMIBC · Persbericht

5/12 · Euronext Brussel: UCB neemt twijfels over Bimzelx-verkoop weg · Tijd.be (€)

Hoop op een Amerikaanse renteknip houdt de beurzen op dreef. Met een hogere jaarprognose stelt UCB beleggers gerust over de vraag naar zijn veelzijdig stermiddel Bimzelx.

5/12 · UCB verhoogt opnieuw financiële verwachtingen voor 2025 · Bolero.be

5/12 · Farmabedrijf UCB verhoogt opnieuw jaarprognose, met dank aan vijf paradepaardjes · Tijd.be (€)

Gestuwd door de sterke verkoop van zijn stermedicijnen verwacht het Belgische farmabedrijf UCB nu over 2025 een omzet van meer dan 7,6 miljard euro en een winstmarge van meer dan 31 procent.

5/12 · Ipsen provides update on legacy of Henri Beaufour · Persbericht

4/12 · Devonian Health Group Announces Publication of Landmark Study Highlighting Thykamine™ as a Promising New Anti-Inflammatory Agent · Persbericht

4/12 · Citius Oncology Expands LYMPHIR™ Distribution to Turkey and Middle East Countries Through Exclusive Agreement with Er-Kim · Persbericht

4/12 · UCB shares leading scientific research and advances at American Epilepsy Society Annual Meeting · Persbericht

4/12 · Trevi Therapeutics Announces Appointment of David Hastings as Chief Financial Officer · Persbericht

4/12 · Press Release: Sanofi completes acquisition of Vicebio · Persbericht

4/12 · Addex Therapeutics Reports 2025 Third Quarter Financial Results and Provides Corporate Update · Persbericht

3/12 · Hoth Therapeutics Issues Comprehensive Pipeline Update Highlighting Clinical Progress, Orphan-Designated HT-KIT, Advancing HT-001 Phase 2, and New GDNF Metabolic Program · Persbericht

3/12 · U.S. FDA approves expanded indication for Lilly's Jaypirca (pirtobrutinib), the first and only non-covalent (reversible) BTK inhibitor, for adults with relapsed or refractory CLL/SLL previously treated with a covalent BTK inhibitor · Persbericht

3/12 · Johnson & Johnson Teams Up with Naomi Watts to Reveal Why an Eye Exam is the Ultimate Self-Care Move for Women Over 40 · Persbericht

3/12 · Crinetics Announces First Patient Dosed in Phase 1/2 Trial Evaluating CRN09682 for the Treatment of Neuroendocrine Tumors and Other Somatostatin Receptor 2-Expressing Tumors · Persbericht

3/12 · ADC Therapeutics Announces Updated Data from LOTIS-7 Phase 1b Clinical Trial of ZYNLONTA® in Combination with Bispecific Antibody Supporting Potential Best-in-Class Regimen in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma · Persbericht

Mijn selecties